OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018
22 févr. 2018 16h02 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned
04 janv. 2018 16h02 HE
|
OncoMed Pharmaceuticals, Inc.
Board of Directors has initiated search to identify successor Office of the President continues to perform the duties of President and CEO Perry Karsen appointed as Chairman of the Board REDWOOD...
OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program
04 janv. 2018 16h02 HE
|
OncoMed Pharmaceuticals, Inc.
Year-end 2017 Cash Balance of $103.1 Million Presentation of Clinical Data on Phase 1 programs expected in 2018 REDWOOD CITY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals,...
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities
27 nov. 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 27, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
02 nov. 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017
24 oct. 2017 16h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence
19 sept. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
13 sept. 2017 08h05 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Second Quarter 2017 Financial Results
02 août 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Wholly-owned Immuno-oncology Candidate GITRL-Fc to enter clinic in 2H 2017 Q2 Cash Balance of $129.8M – Cash Through Q3 2019 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET...
OncoMed Pharmaceuticals to Report Second Quarter Financial Results on August 2nd, 2017
26 juil. 2017 16h25 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...